Which is the preferred infusion therapy (Efgartigimod alfa, eculizumab or ravulizumab) for patients not responding to oral treatment with Seropositive Generalized Myasthenia?   

This is one of the most “hot topics” in neuromuscular as of 9/2022. For Introduction purposes, efgartigimod is a monoclonal antibody targeting the neonatal FcRn receptor. This receptor leads to Immunoglobulin “recycling” ie return of IgGs to the blood. Blocking this receptor ...